We are excited to announce that our recently CE-marked MosaiQ® AiPlex CTD microarray immunoassay, which aims to shorten time-to-diagnosis for autoimmune patients, is now available in over 35 markets across Europe and the Asia Pacific region.
The MosaiQ AiPlex CTD solution is designed to aid in the diagnosis of multiple Connective Tissue Diseases, including Systemic Lupus Erythematosus (SLE), Sjögren’s Syndrome, Scleroderma (Systemic Sclerosis), Polymyositis / Dermatomyositis, and Mixed Connective Tissue Disease (MCTD). The easy-to-use and innovative MosaiQ AiPlex CTD solution aims to provide multimodal, multiplexed testing that brings clinical and economic value to laboratories while streamlining their operations.
“We are committed to empowering diagnostic insights, transforming patient care, and innovating for life. These certifications demonstrate our commitment to product quality and safety. We are eager to help reduce diagnostic turnaround times for patients in these regions,” said Manuel O. Méndez, Chief Executive Officer of AliveDx.
Would you like to know more about our MosaiQ solution? Click here:
